Watermark
  Back to Search Results

BGB-A317-211

Completed

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-211

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT04401800

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20200972

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / 70 Years

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / 70 Years

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan